By Wayne Koberstein, Executive Editor, Life Science Leader magazine
Follow Me On Twitter @WayneKoberstein
Pursuing drug treatments for all sufferers of Dupuytren’s and other fibroproliferative diseases
Ventoux Biosciences is an early-stage biopharma startup in preclinical development of medications for treating Dupuytren’s disease (palmar fibromatosis) and related fibrotic diseases. The company is developing two lead candidates, coded VEN-201 and VEN-202, for the same indications: Dupuytren’s, which causes painful deformities in the hand, and Ledderhose disease (plantar fibromatosis), which produces hard growths on the bottom of the foot.